SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1×1 meetings at the following upcoming investor conferences:
- Presentation at the H.C. Wainwright 25th Annual Global Investment Conference on September 13 at 10AM ET
- Fireside chat at the 2023 Cantor Global Healthcare Conference on September 26 at 3PM ET
A live webcast of both events will be available on the “Events and Presentations” page of the Investors section of the Company’s website with a replay available for 30 days following the event. For more information, please visit investors.effector.com.
About eFFECTOR Therapeutics
eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.
Contacts:
| Investors: | Media: | |||
| Christopher M. Calabrese Managing Director LifeSci Advisors 917-680-5608 [email protected] |
Kevin Gardner Managing Director LifeSci Advisors 617-283-2856 [email protected] |
Mike Tattory Account Supervisor LifeSci Communications 609-802-6265 [email protected] |
